Mechanisms of growth inhibition of primary prostate epithelial cells following gamma irradiation or photodynamic therapy include senescence, necrosis, and autophagy, but not apoptosis

Cancer Medicine

Volumn 5, Issue 1, 2016, Pages 61-73

  Frame, Fiona M ^a   Savoie, Huguette ^b   Bryden, Francesca ^b   Giuntini, Francesca ^c   Mann, Vincent M ^d,e   Simms, Matthew S ^d,e   Boyle, Ross W ^b   Maitland, Norman J ^a  

^a UNIVERSITY OF YORK   (United Kingdom)

^b UNIVERSITY OF HULL   (United Kingdom)

^c LIVERPOOL JOHN MOORES UNIVERSITY   (United Kingdom)

^d HULL AND EAST YORKSHIRE HOSPITALS NHS TRUST   (United Kingdom)

^e UNIVERSITY OF HULL   (United Kingdom)

Author keywords

Cancer stem like cells; Photodynamic therapy; Prostate cancer; Radiotherapy

Indexed keywords

5 [[(AMINOBUTYL N OXYCARBONYL)PHENYL]PHENYL] 10,15,20 TRIS(N METHYL 4 PYRIDINIUM)PORPHYRIN TRICHLORIDE; DNA; HISTONE H2AX; PHOTOSENSITIZING AGENT; PORPHYRIN DERIVATIVE; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG;

ADULT; AGED; APOPTOSIS; ARTICLE; AUTOPHAGY; CANCER INHIBITION; CELL AGING; CELL CULTURE; CELL DEATH; CELL GROWTH; CELL VIABILITY; COLONY FORMATION; CONTROLLED STUDY; DNA DAMAGE; DRUG EFFECT; GAMMA IRRADIATION; GENE EXPRESSION; HUMAN; HUMAN CELL; IC50; MALE; MIDDLE AGED; OXIDATIVE STRESS; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE EPITHELIUM CELL; PROSTATE HYPERTROPHY; PROSTATECTOMY; THERAPY EFFECT; TRANSURETHRAL RESECTION; ADVERSE EFFECTS; CELL PROLIFERATION; CELL SURVIVAL; CYTOLOGY; DRUG EFFECTS; EPITHELIUM CELL; GAMMA RADIATION; GENETICS; METABOLISM; PATHOLOGY; PHOTOCHEMOTHERAPY; PROSTATE; PROSTATIC NEOPLASMS; RADIATION RESPONSE; STEM CELL;

APOPTOSIS; AUTOPHAGY; CELL AGING; CELL PROLIFERATION; CELL SURVIVAL; CELLS, CULTURED; DNA DAMAGE; EPITHELIAL CELLS; GAMMA RAYS; HUMANS; MALE; OXIDATIVE STRESS; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; PROSTATE; PROSTATIC NEOPLASMS; REACTIVE OXYGEN SPECIES; STEM CELLS;

EID: 85006219612     PISSN: None     EISSN: 20457634     Source Type: Journal    
DOI: 10.1002/cam4.553     Document Type: Article

References (51)

1. Zerbib, M., M. J. Zelefsky, C. S. Higano, and P. R. Carroll . 2008. Conventional treatments of localized prostate cancer. Urology 72:S25-S35.
2. Duchesne, G. 2011. Localised prostate cancer - current treatment options. Aust. Fam. Physician 40:768-771.
3. Kollmeier, M. A., and M. J. Zelefsky . 2011. Brachytherapy for clinically localized prostate cancer: optimal patient selection. Arch. Esp. Urol. 64:847-857.
4. Koontz, B. F., and W. R. Lee . 2011. External beam radiation therapy for clinically localized prostate cancer: when and how we optimize with concurrent hormonal deprivation. Arch. Esp. Urol. 64:858-864.
5. Aizer, A. A., X. Gu, M. H. Chen, T. K. Choueiri, N. E. Martin, J. A. Efstathiou, et al. 2015. Cost implications and complications of overtreatment of low-risk prostate cancer in the United States. J. Natl. Compr. Canc. Netw. 13:61-68.
6. Lindner, U., J. Trachtenberg, and N. Lawrentschuk . 2010. Focal therapy in prostate cancer: modalities, findings and future considerations. Nat. Rev. Urol. 7:562-571.
7. Lee, J., and C. Moon . 2011. Current status of experimental therapeutics for head and neck cancer. Exp. Biol. Med. (Maywood) 236:375-389.
8. Wildeman, M. A., H. J. Nyst, B. Karakullukcu, and B. I. Tan . 2009. Photodynamic therapy in the therapy for recurrent/persistent nasopharyngeal cancer. Head Neck Oncol. 1:40.
9. Allison, R., K. Moghissi, G. Downie, and K. Dixon . 2011. Photodynamic therapy (PDT) for lung cancer. Photodiagnosis Photodyn. Ther. 8:231-239.
10. Choudhary, S., J. Tang, M. L. Elsaie, and K. Nouri . 2011. Lasers in the treatment of nonmelanoma skin cancer. Dermatol. Surg. 37:409-425.
11. Gold, M. H. 2011. Photodynamic therapy. Curr. Probl. Dermatol. 42:181-192.
12. Arumainayagam, N., C. M. Moore, H. U. Ahmed, and M. Emberton . 2010. Photodynamic therapy for focal ablation of the prostate. World J. Urol. 28:571-576.
13. Moore, C. M., M. Emberton, and S. G. Bown . 2011. Photodynamic therapy for prostate cancer-an emerging approach for organ-confined disease. Lasers Surg. Med. 43:768-775.
14. Pinto, F., A. Totaro, A. Calarco, E. Sacco, A. Volpe, M. Racioppi, et al. 2011. Imaging in prostate cancer diagnosis: present role and future perspectives. Urol. Int. 86:373-382.
15. Postiglione, I., A. Chiaviello, and G. Palumbo . 2011. Enhancing photodynamyic therapy efficacy by combination therapy: dated, current and oncoming strategies. Cancers 3:2597-2629.
16. Petri, A., D. Yova, E. Alexandratou, M. Kyriazi, and M. Rallis . 2012. Comparative characterization of the cellular uptake and photodynamic efficiency of Foscan(R) and Fospeg in a human prostate cancer cell line. Photodiagnosis Photodyn. Ther. 9:344-354.
17. Xu, D. D., H. M. Lam, R. Hoeven, C. B. Xu, A. W. Leung, and W. C. Cho . 2013. Photodynamic therapy induced cell death of hormone insensitive prostate cancer PC-3 cells with autophagic characteristics. Photodiagnosis Photodyn. Ther. 10:278-287.
18. Yamauchi, M., N. Honda, H. Hazama, S. Tachikawa, H. Nakamura, Y. Kaneda, et al. 2014. A novel photodynamic therapy for drug-resistant prostate cancer cells using porphyrus envelope as a novel photosensitizer. Photodiagnosis Photodyn. Ther. 11:48-54.
19. Hudson, R., M. Carcenac, K. Smith, L. Madden, O. J. Clarke, A. Pelegrin, et al. 2005. The development and characterisation of porphyrin isothiocyanate-monoclonal antibody conjugates for photoimmunotherapy. Br. J. Cancer 92:1442-1449.
20. Palumbo, A., F. Hauler, P. Dziunycz, K. Schwager, A. Soltermann, F. Pretto, et al. 2011. A chemically modified antibody mediates complete eradication of tumours by selective disruption of tumour blood vessels. Br. J. Cancer 104:1106-1115.
21. Sutton, J. M., O. J. Clarke, N. Fernandez, and R. W. Boyle . 2002. Porphyrin, chlorin, and bacteriochlorin isothiocyanates: useful reagents for the synthesis of photoactive bioconjugates. Bioconjug. Chem. 13:249-263.
22. Frame, F. M., D. Pellacani, A. T. Collins, M. S. Simms, V. M. Mann, G. D. Jones, et al. 2013. HDAC inhibitor confers radiosensitivity to prostate stem-like cells. Br. J. Cancer 109:3023-3033.
23. Brawer, M. K. 2002. Radiation therapy failure in prostate cancer patients: risk factors and methods of detection. Rev. Urol. 4(Suppl 2):S2-S11.
24. Collins, A. T., P. A. Berry, C. Hyde, M. J. Stower, and N. J. Maitland . 2005. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res. 65:10946-10951.
25. Kramarenko, G. G., S. G. Hummel, S. M. Martin, and G. R. Buettner . 2006. Ascorbate reacts with singlet oxygen to produce hydrogen peroxide. Photochem. Photobiol. 82:1634-1637.
26. Hamid, R., Y. Rotshteyn, L. Rabadi, R. Parikh, and P. Bullock . 2004. Comparison of alamar blue and MTT assays for high through-put screening. Toxicol. In Vitro 18:703-710.
27. Birnie, R., S. D. Bryce, C. Roome, V. Dussupt, A. Droop, S. H. Lang, et al. 2008. Gene expression profiling of human prostate cancer stem cells reveals a pro-inflammatory phenotype and the importance of extracellular matrix interactions. Genome Biol. 9:R83.
28. Ulukaya, E., F. M. Frame, B. Cevatemre, D. Pellacani, H. Walker, V. M. Mann, et al. 2013. Differential cytotoxic activity of a novel palladium-based compound on prostate cell lines, primary prostate epithelial cells and prostate stem cells. PLoS ONE 8:e64278.
29. Diehn, M., R. W. Cho, N. A. Lobo, T. Kalisky, M. J. Dorie, A. N. Kulp, et al. 2009. Association of reactive oxygen species levels and radioresistance in cancer stem cells. Nature 458:780-783.
30. Schumacker, P. T. 2006. Reactive oxygen species in cancer cells: live by the sword, die by the sword. Cancer Cell 10:175-176.
31. Pelicano, H., D. Carney, and P. Huang . 2004. ROS stress in cancer cells and therapeutic implications. Drug Resist. Updates 7:97-110.
32. Gibellini, L., M. Pinti, M. Nasi, S. De Biasi, E. Roat, L. Bertoncelli, et al. 2010. Interfering with ROS metabolism in cancer cells: the potential role of quercetin. Cancers 2:1288-1311.
33. Wang, J., and J. Yi . 2008. Cancer cell killing via ROS: to increase or decrease, that is the question. Cancer Biol. Ther. 7:1875-1884.
34. Schumacker, P. T. 2015. Reactive oxygen species in cancer: a dance with the devil. Cancer Cell 27:156-157.
35. Trachootham, D., J. Alexandre, and P. Huang . 2009. Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach? Nat. Rev. Drug Discovery 8:579-591.
36. Altman, B. J., and J. C. Rathmell . 2012. Metabolic stress in autophagy and cell death pathways. Cold Spring Harb. Perspect. Biol. 4:a008763.
37. Yonekawa, T., and A. Thorburn . 2013. Autophagy and cell death. Essays Biochem. 55:105-117.
38. Giuntini, F., C. M. Alonso, and R. W. Boyle . 2011. Synthetic approaches for the conjugation of porphyrins and related macrocycles to peptides and proteins. Photochem. Photobiol. Sci. 10:759-791.
39. Kuruppuarachchi, M., H. Savoie, A. Lowry, C. Alonso, and R. W. Boyle . 2011. Polyacrylamide nanoparticles as a delivery system in photodynamic therapy. Mol. Pharm. 8:920-931.
40. Huang, Y. H., P. M. Yang, Q. Y. Chuah, Y. J. Lee, Y. F. Hsieh, C. W. Peng, et al. 2014. Autophagy promotes radiation-induced senescence but inhibits bystander effects in human breast cancer cells. Autophagy 10:1212-1228.
41. Liao, E. C., Y. T. Hsu, Q. Y. Chuah, Y. J. Lee, J. Y. Hu, T. C. Huang, et al. 2014. Radiation induces senescence and a bystander effect through metabolic alterations. Cell Death Dis. 5:e1255.
42. Robertson, C. A., D. H. Evans, and H. Abrahamse . 2009. Photodynamic therapy (PDT): a short review on cellular mechanisms and cancer research applications for PDT. J. Photochem. Photobiol., B 96:1-8.
43. Price, M., S. R. Terlecky, and D. Kessel . 2009. A role for hydrogen peroxide in the pro-apoptotic effects of photodynamic therapy. Photochem. Photobiol. 85:1491-1496.
44. Davies, K. J. 1999. The broad spectrum of responses to oxidants in proliferating cells: a new paradigm for oxidative stress. IUBMB Life 48:41-47.
45. Hirst, A. M., M. S. Simms, V. M. Mann, N. J. Maitland, D. O'Connell, and F. M. Frame . 2015. Low-temperature plasma treatment induces DNA damage leading to necrotic cell death in primary prostate epithelial cells. Br. J. Cancer 112:1536-1545.
46. Han, W., and K. N. Yu . 2010. Ionizing radiation, DNA double strand break and mutation. In: urbano KV. Adv. Genet. Res., 4:1-13.
47. Nowis, D., M. Makowski, T. Stoklosa, M. Legat, T. Issat, and J. Golab . 2005. Direct tumor damage mechanisms of photodynamic therapy. Acta Biochim. Pol. 52:339-352.
48. Colasanti, A., A. Kisslinger, M. Quarto, and P. Riccio . 2004. Combined effects of radiotherapy and photodynamic therapy on an in vitro human prostate model. Acta Biochim. Pol. 51:1039-1046.
49. Boukaram, C., and J. M. Hannoun-Levi . 2010. Management of prostate cancer recurrence after definitive radiation therapy. Cancer Treat. Rev. 36:91-100.
50. Trachtenberg, J., A. Bogaards, R. A. Weersink, M. A. Haider, A. Evans, S. A. McCluskey, et al. 2007. Vascular targeted photodynamic therapy with palladium-bacteriopheophorbide photosensitizer for recurrent prostate cancer following definitive radiation therapy: assessment of safety and treatment response. J. Urol. 178:1974-1979; discussion 9.
51. Freitag, L., A. Ernst, M. Thomas, R. Prenzel, B. Wahlers, and H. N. Macha . 2004. Sequential photodynamic therapy (PDT) and high dose brachytherapy for endobronchial tumour control in patients with limited bronchogenic carcinoma. Thorax 59:790-793.